key: cord-1007009-l11k5jr6
authors: Garvey, Mark I.; Wilkinson, Martyn A C; Holden, Elisabeth; Shields, Adrian; Robertson, Alastair; Richter, Alex; Ball, Simon
title: Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre
date: 2021-04-29
journal: J Infect
DOI: 10.1016/j.jinf.2021.04.027
sha: 5c4753b04d00cfdf81ccea16651d6e3a118409d5
doc_id: 1007009
cord_uid: l11k5jr6

nan

 The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the rapid development of multiple vaccines which have been rolled out worldwide.

 In the first phase of the UK vaccine programme, HCWs were among the first to be vaccinated. This offered an opportunity to observe the effect in one the largest groups of HCWs in the UK.

 Our preliminary data suggests one dose of the vaccine is affording some protection and the probability of a member of staff testing positive for SARS CoV-2 given that they have been vaccinated with one dose is lower than for staff who have not been vaccinated.

 However, a proportion of our vaccinated HCW are still acquiring SARS-CoV-2, an important message being that one dose of the vaccination will not prevent individuals from getting COVID-19 and potentially transmitting it.

 We conclude that it is imperative staff remain vigilant once they are vaccinated, due to the ongoing potential for onwards transmission to patients and other HCWs.

The pandemic of severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) has precipitated the most extensive global vaccine development programme in history and has resulted in several vaccines receiving emergency use authorisation. 1 Here, we report preliminary observations on the impact of a healthcare worker Carlo modelling to analyse the Israel data. 4 They found after initial injection, case numbers increased to day 8 before declining to low levels by day 21. 4 Estimating vaccine effectiveness, they concluded this was 0 at day 14 but then rose to about 90% at day 21 before levelling off. 4 They concluded the cause of the initial surge in infection risk may be related to people being less cautious about maintaining protective behaviours as soon as they have the injection. 4 This could also be a plausible reason why we see a significant numbers of our vaccinated HCWs being positive for SARS-CoV-2. Our data set is unique as we are looking specifically at HCWs. In our population, HCWs would be exposed to higher viral loads and infectious cases. As a result, they are more likely to get infections from SARS-CoV-2 than the general population, as per the work of Shields et al., (2020). 5 It is unsurprising we see a high proportion of vaccinated HCWs testing positive. We saw the same phenomenon of vaccinated HCWs being positive in the lateral flow antigen tests. Mahese (2020) reported that the lateral flow antigen tests will identify infected individuals with the highest viral loads. 6 We saw a significant proportion of our vaccinated infected HCWs positive via lateral flow, implying these HCWs could have higher viral loads. There is debate whether vaccinated individuals transmit SARS-CoV-2, however the fact a proportion of our vaccinated HCWs are positive on lateral flow tests suggestive of high viral loads, implies they will be a vector for transmission. This is further supported by the fact that 70% of our positive HCWs reported symptoms, thus increasing likelihood of transmission.

It is an important message, not just for HCW but for the wider public, that one dose of the vaccination will not prevent individuals from getting COVID-19 and potentially transmitting it. Will a second vaccination reduce HCWs having a high viral load? The 7 clinical trial data showed the first dose of BNT162b2 having 52% efficacy (like our HCW data) and 2 doses having 95% efficacy. 7 This data supports HCWs having a second dose as a priority, to prevent spread in our vulnerable settings.

We conclude that it is imperative staff remain vigilant once they are vaccinated as we are still detecting a significant number of staff acquiring COVID-19, with the potential for onwards transmission to patients and other HCWs. We have also shown that the probability of our staff getting COVID-19 is reducing with a single dose of the vaccine and this is likely to decrease further once HCWs receive their second dose. 

All authors have contributed to the manuscript.

None, paper is of interest to patients and public in light of current pandemic. An observational study.

The author affirms the manuscript is an honest accurate and transparent account of the study being reported; that no important aspects of the study have been omitted;

and that any discrepancies from the study as planned have been explained.

Israel paper Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

The R Foundation for Statistical Computing

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence

Estimating the effectiveness of the Pfizer

A reanalysis of a study of 'real-world' vaccination outcomes from Israel. medRxiv preprint 2021

SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross sectional study

Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

We would like to thank the Infection Prevention and Control team, the Occupational Health team, the Infection Service, the Clinical Immunology Service, Informatics, the 11 UHB vaccination hospitals hub team and the senior responsible clinicians at University Hospitals Birmingham NHS Foundation Trust. Figure 1